Back to Search
Start Over
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to
- Source :
- Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
- Publication Year :
- 2024
- Publisher :
- Taylor & Francis Group, 2024.
-
Abstract
- Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2 to
- Subjects :
- Atopic dermatitis
pediatric
baricitinib
Dermatology
RL1-803
Subjects
Details
- Language :
- English
- ISSN :
- 09546634 and 14711753
- Volume :
- 35
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of Dermatological Treatment
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.60c95020afe746ab9bb7dbef4c3fa42d
- Document Type :
- article
- Full Text :
- https://doi.org/10.1080/09546634.2024.2411834